Stock UCBJY UCB SA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings UCB SA OTC Markets

Equities

UCBJY

US9034801012

Market Closed - OTC Markets
Other stock markets
 03:52:12 2024-07-16 pm EDT 		5-day change 1st Jan Change
77.77 USD -0.71% Intraday chart for UCB SA -0.04% +78.37%
Jun. 20 Kepler Cheuvreux Downgrades UCB to Hold from Buy, Raises PT MT
Jun. 13 UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.14 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
UCB SA Stock UCB SA
+78.37% 29.79B -
CSL LIMITED Stock CSL Limited
+7.40% 101B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+8.42% 42.18B
A-
BIOGEN INC. Stock Biogen Inc.
-13.04% 32.26B
B-
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-10.92% 16.06B
C
INCYTE CORPORATION Stock Incyte Corporation
+1.93% 14.45B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-6.77% 12.01B
D+
ALTEOGEN INC. Stock ALTEOGEN Inc.
+177.16% 10.71B
D
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.12% 8.89B
B+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-56.13% 8.83B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. UCB Stock
  4. UCBJY Stock
  5. Ratings UCB SA